How big is Seer, Inc. (California)?

As of Jun 18, Seer, Inc. (California) has a market capitalization of 115.34 million and reported net sales of 15.26 million, with a net profit loss of 85.87 million. Shareholder's funds are 327.57 million, and total assets are 366.60 million.

As of Jun 18, Seer, Inc. (California) has a market capitalization of 115.34 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 15.26 million for the latest four quarters. However, it also experienced a net profit loss of 85.87 million during the same period.<BR><BR>As of Dec 24, the company's shareholder's funds amounted to 327.57 million, while total assets were reported at 366.60 million.

What does Seer, Inc. (California) do?

Seer, Inc. (California) is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $4 million and a net loss of $20 million as of March 2025, with a market cap of $115.34 million. Key metrics include a negative P/E ratio, a debt-equity ratio of -0.76, and a return on equity of -27.61%.

Overview: <BR>Seer, Inc. (California) operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 4 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -20 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 115.34 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.76 <BR>Return on Equity: -27.61% <BR>Price to Book: 0.37<BR><BR>Contact Details: <BR>Registrar Address: Not available.

Should I buy, sell or hold Seer, Inc. (California)?

Is Seer, Inc. (California) overvalued or undervalued?

Seer, Inc. is currently considered risky and overvalued due to negative financial metrics, despite a recent 24.29% return outperforming the S&P 500, while its long-term outlook is troubling with a 3-year return of -74.03%.

As of 12 August 2021, the valuation grade for Seer, Inc. has moved from does not qualify to risky. The company appears to be overvalued given its negative financial metrics, including a Price to Book Value of 0.43, an EV to EBITDA ratio of 1.15, and a ROE of -27.61%. Comparatively, peers such as Harpoon Therapeutics, Inc. show a much higher EV to EBITDA of -13.41, indicating that Seer, Inc. is not only underperforming but also carries a higher risk profile.<BR><BR>In terms of recent performance, Seer, Inc. has outperformed the S&P 500 over the past year with a return of 24.29% compared to the index's 17.14%. However, the long-term outlook is concerning, as evidenced by a staggering 3-year return of -74.03% against the S&P 500's 70.41%, reinforcing the notion that the company is currently overvalued.

Is Seer, Inc. (California) technically bullish or bearish?

As of August 20, 2025, Seer, Inc. shows a mildly bearish trend despite outperforming the S&P 500 over the past year, with a return of 24.29% compared to the S&P's 17.14%, but significantly underperformed over three years with a return of -74.03% versus the S&P's 70.41%.

As of 20 August 2025, the technical trend for Seer, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages and the weekly MACD and KST indicators, both indicating bearish momentum. The weekly OBV also confirms bearish sentiment. While the monthly MACD and KST show mildly bullish signals, they are outweighed by the bearish indicators in the shorter time frames. <BR><BR>In terms of performance, Seer, Inc. has outperformed the S&P 500 over the past year with a return of 24.29% compared to the S&P's 17.14%, but it has significantly underperformed over the 3-year period, with a return of -74.03% versus the S&P's 70.41%.